BENITIONSClinical Trial Intelligence

Continuous Glucose Monitoring Following Hospital Discharge

不适用 进行中(已停止招募) NCT05360056

适应症Type 2 Diabetes
分期不适用
申办方Kathleen Dungan
状态进行中(已停止招募)
受试者人数108 人
干预(药物)DexCom G6
开始日期2022年4月26日
完成日期2024年8月31日
结果公布日2025年12月9日

摘要

In this 12-week prospective observational cohort study, hospitalized insulin-requiring patients with T2D will receive a Dexcom continuous glucose monitor (CGM) to wear post-hospital discharge. Patients will complete surveys assessing patient-reported outcomes prior to CGM use and following completion of the study. CGM data will be captured by the patient smartphone app and analyzed. Patients will receive personalized CGM targets and alerts for hyperglycemia and hypoglycemia. Customized reports/ decision support will be sent to the usual diabetes provider. The initial observational cohort study design will be followed by an extension phase of 12 weeks in which data on continuation of use and glucose control will be collected but no further reports will be communicated to providers.

Change in TIR 70-180 mg/dl

12 weeks · percentage of time spent 70-180 mg/dl

Dexcom CGM8.5 ± 28 percentage of time spent 70-180 mg/dl
p-value0.03
Mean Difference (Net)8.51

% Wear Time >70%

12 weeks · Participants

Dexcom CGM54 Participants

DTSQc Score

12 weeks · score on a scale

Dexcom CGM8 score on a scale
p-value<0.0001
Wilcoxon signed rank9.85

在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文

同一适应症的其他试验

全部试验

本页整理自 ClinicalTrials.gov 的公开数据,不构成医疗建议,也不构成投资建议。请务必咨询专业医师。